Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Abbott Unveils New STARLIMS Mobile Apps and Cloud Services for Use in Laboratories

Published: Tuesday, May 07, 2013
Last Updated: Tuesday, May 07, 2013
Bookmark and Share
Version 11 of STARLIMS LIMS software ideal for industrial, clinical and research laboratories

Abbott unveiled Version 11 STARLIMS LIMS software for industrial, clinical and research laboratories, featuring easy and reliable mobile applications for use with smart phones and tablet computing devices. The company also announced global availability of its secure and convenient cloud computing services.

Based on Abbott’s STARLIMS informatics technology, the v.11 LIMS software will expand user functionality to include mobile-device applications and advanced analytic capabilities. These features will allow STARLIMS users to work on the right screen for the right task with an expanded platform to access LIMS information anywhere for use in quality assurance functions, raw materials analysis and other needs.

At the annual Pittcon Laboratory Science and Equipment Exhibition, Abbott showed how its unified STARLIMS platform and new mobile applications offer efficient ways to consolidate and retrieve all types of lab information. STARLIMS is web-based and includes the award-winning Laboratory Information Management Systems (LIMS), as well as Electronic Laboratory Notebook (ELN) functionality and a Scientific Data Management System (SDMS).

Mobile Apps for Use with Smart Phones and Tablets

STARLIMS v.11 software runs on alternative browsers and includes support for  mobile applications for use with STARLIMS systems. The software allows users to access STARLIMS on Chrome, Safari and other browsers and to display LIMS information on tablet computers and smart phones. Two new control libraries are included in STARLIMS v.11 software: one for forms to be run on desktop computers using a range of popular browsers and the other contains controls commonly found on tablets and smart phones that use touch screens. The touch controls allow user interaction with Apple and Android devices in a manner consistent with what users of such devices would expect.

“Selecting the right screen for the right task enables lab managers and other personnel to utilize specially developed apps. Theseapps  provide clients for example, on-the-spot access to lab test results and reports allowing them to  authorize and release lab results remotely. ,” said Clive Baron, general manager, global operations, Informatics Systems, Abbott. “This innovation provides laboratories with broad functionality and unprecedented remote LIMS access and versatility.”

Cloud Services

STARLIMS Cloud Services combines industry-leading, web-based LIMS software with the convenient, versatile and cost-effective reliability of a cloud-based solution. The STARLIMS Cloud is a secure application with a powerful server and storage capabilities managed by STARLIMS which is fully accessible by a web browser.

With STARLIMS Cloud Services, there is no hardware or software to purchase and install and no need to reconfigure existing system infrastructure. Also, data is stored in a secure, cloud-based infrastructure and is delivered, managed and accessed via the STARLIMS application. The STARLIMS Cloud Services team manages the cloud infrastructure, application performance and database monitoring.

STARLIMS offers best-in-class cloud environments, public or private. With the STARLIMS Public Cloud, customers can work in their STARLIMS environment directly via the Internet. Users also can access STARLIMS as an extension of an internal network with the STARLIMS Private Cloud via secure connections such as IPSec or MPLS.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abbott Completes Acquisition of Topera, Inc.
Company acquire all outstanding equity of Topera for $250 million upfront.
Tuesday, January 06, 2015
Abbott to Acquire Veropharm
The acquisition of the Russian pharmaceutical manufacturer is in keeping with the long term commitment to provide healthcare products to Russian patients.
Monday, June 23, 2014
Partners In Health, Abbott and the Abbott Fund Open Nutrition Facility in Haiti
Facility produces first shipments of locally sourced, therapeutic food to treat severe malnutrition in children.
Monday, November 11, 2013
Abbott Completes Separation of Research-Based Pharmaceuticals Business
Set to deliver industry-leading growth, expanding margins and strong cash flow.
Monday, January 07, 2013
Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval
HUMIRA is now indicated to treat adult patients with moderate to severe ulcerative colitis who have had an inadequate response to immunosuppressants.
Thursday, October 04, 2012
Abbott to Collaborate with Astellas Pharma
The companies will collaborate in a Phase 3 clinical trial for ASP0113, an investigational vaccine for preventing cytomegalovirus reactivation in transplant patients.
Thursday, September 06, 2012
Leading Agent in the Treatment of Psosiasis
Abbott/Eisai's Humira has emerged on top with major-market sales of more than $1.4 billion in 2011.
Tuesday, August 07, 2012
Abbott Licenses Prostate Cancer Biomarkers
The exclusive license from Stanford University for several novel biomarkers could help develop a molecular diagnostic test that differentiates aggressive from nonaggressive prostate cancer.
Wednesday, April 18, 2012
Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company
Abbott Remains on Track for Separation into Two Publicly Traded Global Health Care Companies by End of 2012
Thursday, March 22, 2012
Abbott's STARLIMS LIMS Technology to be Installed in FDA Testing Laboratories
FDA will begin implementing the software-based LIMS as part of the agency's initiative to enhance FDA testing laboratories by managing complex processes and analysing the vast amount of information generated.
Thursday, January 19, 2012
Abbott and University of Illinois Establish Center for Nutrition, Learning and Memory
The companies have established the first-ever multi-disciplinary nutrition and cognition research center,. The Center for Nutrition, Learning, and Memory will lead directed and solicited research on the impact of nutrition on learning and memory in the human brain.
Tuesday, December 20, 2011
Abbott and Reata Pharmaceuticals Announce Agreement for Next-Generation Antioxidant Inflammation Modulators
The companies announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators (AIMs).
Wednesday, December 14, 2011
Abbott Expands Agreement with GSK to Include Development of a Companion Diagnostic Test
Companion diagnostic tests identify specific DNA sequences for cancer immunotherapy antigen.
Tuesday, November 29, 2011
FDA Approves First Supplemental Test for Chagas Disease
The U.S. Food and Drug Administration have approved the first test for use as an additional, more specific test on human serum or plasma specimens found to be positive for antibodies to T. cruzi, which causes Chagas disease, a serious and potentially fatal parasitic infection.
Monday, November 21, 2011
Abbott Presents Data Exploring Relationship of Physical Function to Inflammation and Structural Damage in Rheumatoid Arthritis
Abbott have presented results from a pooled analysis of two pivotal HUMIRA(R) (adalimumab) studies, which look at patients with early and long-standing moderate to severe rheumatoid arthritis (RA), at the American College of Rheumatology meeting in Atlanta. The study looked at inflammation and structural damage of the joints in early and long-standing RA and their relationship with deteriorating physical function in each stage of the disease.
Wednesday, November 17, 2010
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.
Insight into Bacterial Resilience and Antibiotic Targets
Variant of CRISPR technology paired with computerized imaging reveals essential gene networks in bacteria.
Advancing Protein Visualization
Cryo-EM methods can determine structures of small proteins bound to potential drug candidates.
Alzheimer’s Protein Serves as Natural Antibiotic
Alzheimer's-associated amyloid plaques may be part of natural process to trap microbes, findings suggest new therapeutic strategies.
Slime Mold Reveals Clues to Immune Cells’ Directional Abilities
Study from UC San Diego identifies a protein involved in the directional ability of a slime mold.
How Do You Kill A Malaria Parasite?
Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite’s skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream. The drugs also seem to trick the parasite into reproducing prematurely.
Illuminating Hidden Gene Regulators
New super-resolution technique visualizes important role of short-lived enzyme clusters.
Supressing Intenstinal Analphylaxis in Peanut Allergy
Study from National Jewish Health shows that blockade of histamine receptors suppresses intestinal anaphylaxis in peanut allergy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!